ArticleCureus2025
Disseminated Intravascular Coagulation in a Patient With Metastatic Adenocarcinoma: A Case of Insidious Progression and Hematologic Complications.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disseminated intravascular coagulation (DIC) is a severe condition characterized by systemic activation of coagulation, resulting in the formation of microthrombi and consumption of clotting factors, leading to a paradoxical risk of both thrombosis and bleeding. Early diagnosis is crucial to initiating appropriate treatment before the condition worsens, as DIC is often associated with a poor prognosis once clinical signs appear. This case report presents a 60-year-old female patient with metastatic adenocarcinoma, initially diagnosed two years prior, who developed acute DIC shortly before her death. Despite an initial presentation of intractable back pain, nausea, and generalized weakness, laboratory findings demonstrated hemolytic anemia and abnormal coagulation, leading to the diagnosis of consumptive coagulopathy secondary to her advanced malignancy. The patient's declining condition was accompanied by worsening laboratory parameters, including elevated prothrombin time, international normalized ratio (INR), and fibrin degradation products, highlighting the insidious progression of DIC in cancer patients, particularly in the context of adenocarcinoma. Although treated with supportive care, including blood transfusions and withdrawal of anticoagulation, she ultimately succumbed to cardiopulmonary arrest. This case emphasizes the importance of early recognition of DIC in oncology patients, especially those with advanced-stage malignancies, as it often manifests in a less aggressive yet equally fatal form compared to DIC seen in conditions such as sepsis or trauma. Additionally, it emphasizes the need for vigilant laboratory monitoring in critically ill cancer patients to facilitate timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.